Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIL95 in Advanced Malignant Solid Tumors and Lymphomas
NCT04651348Phase 1Recruiting
- Sponsor
- Beijing Tianguangshi Pharmaceutical Technology
- Start
- Jan 2021
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MIL95 in solid tumor and lymphoma, sponsored by Beijing Tianguangshi Pharmaceutical Technology. Primary endpoint: Percentage of Participants with Adverse Events at 1 year. Started Jan 2021; status: recruiting.
02
Drugs
MIL95
03
Conditions
solid tumorlymphoma
Beyond the preview
Go deeper on NCT04651348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04651348.